LTZ Therapeutics
Agent50 out of 100, Top 25%. Agent Readiness. Open the scores section.Agent Readiness: 50/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust71 out of 100, Above median. Data Trust. Open the scores section.Data Trust: 71/100. Above median. Measured by StartupHub.ai. Median 61.Immunotherapy company targeting oncology and autoimmune diseases.
About
LTZ Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies that empower myeloid cells to enhance anti-tumor immunity. Their Universal Myeloid Cell Engager (U-MCETM) platform aims to address unmet clinical needs in oncology and autoimmune diseases by directly engaging myeloid cells to activate killing mechanisms and reprogram the tumor microenvironment.
Listed competitors
Biopharmaceutical company focused on developing and commercializing innovative medicines.
Pioneering biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines to treat patients with serious or life-threatening medical conditions.
A global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
Also in this space
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.
Shares Biotechnology, Drug Discovery
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, HealthTech
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Biotech
Key facts
- Website
- ltztherapeutics.com
- Headquarters
- Redwood City, California, USA
- Founded
- 2021
- Total funding
- $76M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 28 Apr 2026 | Series B | $38M | |
| 26 Jan 2023 | Series A | $38M | Deerfield Management |
Tech stack
Detected on ltztherapeutics.com, last scanned 28 Oct 2026. Run your own scan
- Hosting
- AWS
- Email provider
- Microsoft 365
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is LTZ Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for LTZ Therapeutics is 71 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has LTZ Therapeutics raised?
LTZ Therapeutics has raised a total of $76M in funding. The most recent round on record is Series B.
SEC filings, insider activity, nonprofit links and pay benchmarks for LTZ Therapeutics:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
